ArticleThe journal of headache and pain2026
Medication overuse headache from a tertiary headache center in Egypt: real-world insights.
Article in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Headache service quality in Egypt: current status, identified gaps, and strategic directions.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication-overuse headache (MOH) is a secondary headache disorder often underrecognized in low- and middle-income countries. This study provides the first real-world data on MOH prevalence and clinical characteristics from a tertiary care center in Egypt.
methodsA cross-sectional study was conducted among 120 patients with primary headaches recruited from the Headache Unit and general outpatient clinics. Patients were classified according to ICHD-3 criteria as MOH or non-MOH. Clinical characteristics, risk factors, medication use, disability using the validated Arabic version of Migraine Disability Assessment questionnaire (MIDAS) and Headache Impact Test (HIT-6), quality of life using Arabic version of Short-Form 12 Health Survey (SF-12), and psychiatric comorbidity were assessed.
resultsThe prevalence of MOH was 65.8%. Chronic migraine was the most common underlying primary headache (80.5%). MOH patients were predominantly female (86.1%) and older, and were less educated than non-MOH patients. Risk factors significantly associated with MOH included insomnia (38% vs. 17.1%), musculoskeletal pain/fibromyalgia (43% vs. 19.5%), and physical inactivity (89.9% vs. 75.6%). The most overused medications were ergot derivatives (88.5%) and triptans (59.3%). MOH patients reported significantly higher headache frequency (mean 24.4 ± 7.1 vs. 11.2 ± 7.6 days/month, p < 0.001), greater disability (MIDAS mean 46.5 ± 28.9 vs. 19.3 ± 22.9, p < 0.001), and poorer quality of life (PCS 43 vs. 49.4; MCS 35 vs. 44, p < 0.01). Depression, anxiety, and stress scores were also significantly higher among MOH patients.
conclusionsMOH is alarmingly prevalent among Egyptian tertiary care patients, especially women with chronic migraine, emphasizing the need for national strategies on over-the-counter analgesic control and structured withdrawal programs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.